


Achaogen
Investor Relations Department
7000 Shoreline Court,
3rd Floor
South San Francisco, CA 94080
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: AKAO

Last Trade:	22.31
Trade Time:	4:00 PM ET Jul 20, 2017
Change:	-0.47  (2.063%)
Day Range	22.21 - 23.03
52-Week Range	3.55 - 27.79
Volume	447,313

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE. In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent a... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jul 13, 2017*
[Achaogen Appoints Dr. Karen Bernstein to its Board of Directors](#)
- Jun 22, 2017*
[Achaogen Announces New Employment Inducement Grants](#)
- Jun 5, 2017*
[Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting](#)
- Jun 1, 2017*
[Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate](#)
- May 31, 2017*
[Achaogen Announces Closing of Public Offering](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 14, 2017*
[Annual Report \(10-K\)](#)
- Apr 26, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2016*
[Quarterly Report \(10-Q\)](#)